Introduction: Anthracyclines are among the most powerful antineoplastic drugs ever developed and, even today, they are widely used according to various association schemes in the onco-hematological field. However, cardiotoxicity remains one of the most feared and characteristic side effects, both short and long term, often causing the premature interruption of therapy or irreversible effects after their suspension. In this article, we want to explain the underlying biological mechanisms, the clinical presentation characteristics and the possible strategies to prevent it. Materials and Methods: A computerized research was carried out for the articles to be inserted through use of international databases PUBMED, RESEARCHGATE and GOOGLE SCHOLAR, by typing in keywords such as “anthracyclines cardiotoxicity” and “cardioprotection strategies for anthracycline toxicity” and related articles. Discussion and Conclusions: The toxicity of these drugs on the heart represents the limiting factor both for their indications and for the success of the therapy, sometimes being the cause of premature interruption or impossibility of use in some patients. It depends especially on the cumulative dose used in the single patient and on the pre- existing risk conditions for the development of these ADRs, both in the short and long term. However, there are strategies that can avoid or reduce the damage, both related to the formulation of the compounds and to the co- administration of other drugs.

BACKGROUND AND AIMS Methadone is a well-known drug for the treatment of heroinopathy but its role as an analgesic is often forgotten, especially in primary and non-specialist medicine settings. In this article we want to describe its characteristics in this application not only for the cessation of painkillers but above all for the management of neuropathic pain and hyperalgesia induced by opioid therapy in the long term. METHODS AND RESULTS We conducted searches in PUBMED and MEDLINE for clinical trials and reviews done on the efficacy and safety of methadone used for analgesia in chronic pain and in the disassuefation from painkillers abuse. Clinical trials and the works found have overall shown that this drug has positive effects on the control of pain especially neuropathic and mixed and on some associated aspects such as the quality of life. DISCUSSION AND CONCLUSIONS Methadone remains a mysterious but at the same time fascinating drug, both for the aura of mystery around its name, frowned upon by both patients and prescribers, but at the same time unparalleled in terms of efficacy for analgesia in cancer pain and not, especially in patients who have lost sensitivity to other opioids even more potent than methadone such as fentanyl. In other words, the efficacy in the cessation of abusers of painkillers both for recreational purposes and secondary to background pain now no longer controlled makes this drug unique as a maintenance therapy.

BACKGROUND AND AIMS Methadone is a well-known drug for the treatment of heroinopathy but its role as an analgesic is often forgotten, especially in primary and non-specialist medicine settings. In this article we want to describe its characteristics in this application not only for the cessation of painkillers but above all for the management of neuropathic pain and hyperalgesia induced by opioid therapy in the long term. METHODS The article was written by referring both to the technical data sheets of the drug and by associating research in paper and online books on databases such as Scopus, PubMed, Cochrane Library and Embase. DISCUSSION AND CONCLUSIONS Methadone remains a mysterious but at the same time fascinating drug, both for the aura of mystery around its name, frowned upon by both patients and prescribers, but at the same time unparalleled in terms of efficacy for analgesia in cancer pain and not, especially in patients who have lost sensitivity to other opioids even more potent than methadone such as fentanyl. In other words, the efficacy in the cessation of abusers of painkillers both for recreational purposes and secondary to background pain now no longer controlled makes this drug unique as a maintenance therapy.

Introduction: The presence of dysphagia is a rather common event, both physiologically in elderly people and the presence of neurological, maxillofacial, or upper digestive pathologies. Many drugs are routinely taken in solid form for the convenience of use, however, in such patients, it becomes difficult to swallow tablets or capsules and it is important to both have liquid alternatives and possibly handle the solid forms correctly. In this article, we want to describe the correct handling of solid pharmaceutical forms or the transition to liquid ones where present. Methodology: the article was written by integrating one's knowledge of pharmacology and pharmaceutical techniques with printed material and online articles extracted from databases google scholar and PubMed. Discussion and Conclusions: The liquid forms, where they exist, are important in the management of drug therapy in the dysphagia patient. In the absence of therapeutic alternatives or liquid forms of the same principle, the solid forms can be manipulated within certain limits, paying attention to the interactions with nutritional mixtures and other drugs and above all not obstructing the probe and not compromising the kinetic and dynamic characteristics of the active ingredient.

INTRODUCTION: In the context of adverse drug reactions (ADR), skin manifestations are among one of the most frequent and often of such severity as to require access to the emergency room for emergency injection therapy. In this article we wanted to describe the characteristics of severe skin reactions both from a clinical point of view and with regard to the mechanisms and drugs most often involved in the cause. METHODS: Both the use of personal paper books and international website databases such as pubmed, scopus, google scholar, researchgate were used to develop the article, typing in keywords such as “ skin ADR”, “severe drug reactions”, “lyell or steven-johnson syndrome”; associated with specific compound names. We have focused on recent articles and only related to severe ADRs. RESULTS AND CONCLUSIONS: With regard to cutaneous ADRs, mild or moderate pictures can be distinguished such as morbilliform or scarlet eruptions with or without systemic symptoms, fortunately more frequent and generally treatable through the use of partially injected drugs and with oral therapy, which self-resolve in a few days. , up to severe and potentially fatal erythrodermal forms such as DRESS or steven-johnson and Lyell's syndromes, two different phases of the same process, with dermatological pictures similar to burns. Lists of higher-risk drugs have been established and every physician, including general practitioners, should know their potential for toxicity before prescribing and the need for closer clinical monitoring. Pay attention to the differential diagnosis with infectious processes, sometimes concomitant, and to primary forms of dermatosis such as severe forms of psoriasis or acne.